Response to first-line treatment and histology are associated with achieving complete remission after the first salvage high-dose chemotherapy in relapsing germ cell tumor patients Abstract Sequential high-dose chemotherapy (HDCT) with autologous stem cell transplantation (ASCT) is a curative option in relapsing germ cell tumor (GCT) patients, and complete remission (CR) after the first ASCT (early CR2) is associated with favorable outcome. Prognostic factors predicting early CR2 have not been investigated so far. We analyzed consecutive patients with a first relapse of GCT treated with three sequential cycles of carboplatin/etoposide-based HDCT with ASCT in the two largest academic centers in Switzerland. The cohort comprised 96 relapsing GCT patients, with 19 (19.8%) patients achieving early CR2 after the first HDCT cycle. The median progression-free survival and overall survival were not reached in patients achieving early CR2, whereas they were 9.6 months (P = 0.0301) and 34.8 months (P = 0.0684) for patients missing early CR2. Patients with early CR2 more often had CR1 after first-line bleomycin, etoposide, and cisplatin chemotherapy (68.4 vs. 31.6%; P = 0.0037) and an interval longer than 2 years between initial diagnosis and first HDCT (36.8 vs. 15.6%; P = 0.0373), but less often a histology of mixed nonseminomatous tumor (46.8 vs. 21.1%; P = 0.0418). These data suggest that response to first-line chemotherapy, late relapse, and histology are associated with achieving early CR2 after a first HDCT with ASCT in relapsing GCT patients.
Introduction
In contrast to virtually all other solid tumor types, high-dose chemotherapy (HDCT) with autologous stem cell transplantation (ASCT) represents a curative salvage strategy in a significant number of patients with relapsing germ cell tumors (GCT) [1] [2] [3] . Relapsing GCTs commonly preserve sensitivity to platinum-based intensive chemotherapy. Accordingly, early studies in the late 1980s pioneered two cycles of HDCT with a dose of 1,500 mg/m 2 of carboplatin and 1,200 mg/m 2 of etoposide (CE-HDCT), divided over 3 days, with subsequent autologous stem cell support as a backbone in relapsed/refractory GCT patient [4] [5] [6] . A variety of strategies have been reported to optimize the efficacy of CE-HDCT comprising escalating dosages of the cytotoxic compounds, including a third cytotoxic drug, modifying the preceding mobilization chemotherapy, or, finally, increasing the number of HDCT cycles [2, [7] [8] [9] [10] . Whereas the optimum number of HDCT cycles with ASCT in relapsed GCTs has so far never been formally proven, the majority of salvage strategies in GCT patients involve at least two HDCT/ASCT cycles [3, 10, 11] . However, factors predicting the number of HDCT/ASCT cycles needed in individual patients with relapsed GCT are not established.
Prognostic parameters in metastatic GCT at diagnosis have been summarized in the International Germ-Cell Cancer Cooperative Group (IGCCCG) classification, whereas prognostic features for patients with relapsed GCT are less clear and such reports are mainly based on small numbers of patients [12] [13] [14] [15] [16] . The following factors were reported to be predictive for treatment failure in relapsed/ refractory GCT patients: primary mediastinal nonseminomatous tumor; aggressive disease before HDCT; disease refractory to conventionally dosed cisplatin therapy preceding HDCT; and human chorionic gonadotropin (HCG) levels >1,000 U/L before HDCT [13] . Finally, an international collaborative effort intended to overcome the limitation of previous small series by retrospectively analyzing a cohort of nearly 1,600 patients [17] . The following prognostic variables for GCT patients failing treatment with cisplatin-based first-line chemotherapy were identified: primary side of tumor; response to first-line chemotherapy; progression-free interval; tumor markers at relapse; and liver, bone, or brain (LBB) metastases. Accordingly, patients were scored in five prognostic categories with differing survival rates.
We previously reported a cohort of relapsing GCT patients planned to receive three cycles of CE-HDCT/ASCT [18] . We found that only those GCT patients in first relapse enjoyed a specific survival benefit from a third cycle of CE-HDCT who achieved early CR2 already after the first CE-HDCT/ASCT. These early CR2 patients particularly benefitted from the entire program of three sequential HDCT cycles with a remarkable 100% progression-free (PFS) and overall survival (OS) rate after 5 years. In the present study, we aimed to identify the prognostic parameters associated with conserved chemosensitivity to high-dose carboplatin and etoposide (CE) leading to CR2 already after the first HDCT/ASCT cycle in relapsing GCT. Such prognostic parameters may turn out to be useful to identify those patients who may benefit from the entire program of three HDCT cycles while separating those patients who may be better allocated to alternative or investigational approaches involving novel immunotherapy concepts, conventional chemotherapy, and/or maintenance strategies.
Patients and methods

Patients
This retrospective study analyzed all consecutive male patients of two academic centers (University Hospitals of Bern and Zurich) in Switzerland with a first relapse of GCT; these patients have received treatment aiming at three cycles of HDCT with carboplatin/etoposide and subsequent ASCT between January 1997 and 2016. All data were prospectively collected based on follow-up reports (at ASCT, 100 days after ASCT, and life-long once a year thereafter) as prescribed by Swiss regulations, and data were provided by the Swiss Blood Stem Cell Transplantation (SBST) organization, with written informed consent of the patients or their parents (for adolescent patients). This study was approved (decision #133/2014) by the ethics committee of Bern, Switzerland. Patients with GCTs were eligible for the study if there was unequivocal evidence of relapse or progression after cisplatin-based combination chemotherapy for metastatic GCT as defined by either increasing tumor markers and/or progressing radiologic manifestations. Marker-negative patients needed additional histologic evidence of relapsing GCT. Patients with mediastinal primaries could be included.
The clinical characteristics of the patients are summarized in Table 1 . The first-line chemotherapy was bleomycin, etoposide, and cisplatin (BEP; in 86 of 95 patients; 90.5%). Three or more first-line chemotherapy cycles were given in 93 of 95 patients (97.9%), whereas the number of cycles remained unknown in two patients. Complete remission (CR) after first-line chemotherapy was achieved in 38.9% (37 of 95 patients). One-third of the patients underwent surgical resection after first-line chemotherapy (31 of 95 patients; 32.6%). The duration between initial diagnosis of GCT and HDCT exceeded 2 years in 19 of 96 patients (19.8%; range 2.1-25.7 years).
Treatment
HDCT comprised CE, with or without an additional third agent. Initial mobilization regimens consisted of one cycle of conventional-dose VIP regimen (etoposide, ifosfamide, and cisplatin) or the TIP regimen (paclitaxel, ifosfamide, and cisplatin), followed by three planned cycles of high- (CE-HDCT), divided over 3 days, followed by reinfusion of autologous peripheral blood progenitor cells. The median number of reinfused CD34+ cells was identical in first, second, and third transplants (4.1 × 10 6 CD34+ cells/kg). Cycles were tentatively repeated at 21-day intervals or longer when clinically indicated. Four patients had a triplet conditioning regimen, with 60 mg/kg cyclophosphamide as a third agent in addition to CE.
Clinical evaluations and follow-up
All patients with a partial remission after completed CE-HDCT were evaluated for surgical resection of residual disease. Clinical follow-up evaluations were performed at the discretion of the local centers. Typically, follow-up evaluations were performed at 6 and 12 weeks after HDCT. Patients were re-evaluated every 3 months during the first year, and every 6 months during subsequent years for an overall period of 3 years. By law, at least one annual followup report to the national SBST authorities was required.
Evaluation typically involved physical examination, laboratory analysis including tumor markers (α-fetoprotein, GCG, and LDH), and computed tomography scan of residual masses or at clinically suspected relapse.
Definitions
CR was defined as negative tumor markers and no evidence of disease by radiological assessment. Early CR2 was defined as seronegative tumor markers after the first cycle of HDCT. OS was defined from the day of the first ASCT until death of any cause or last follow-up of patients alive. The time until progression was the time from the day of first ASCT until first subsequent progression or death, whichever occurred first. Patients in ongoing remission were censored at the time they were last known to be alive.
Statistical analysis
Survival probabilities were calculated according to the method of Kaplan and Meier [19] . Analyses were using the GraphPadPrism (Version 6.0b, GraphPad Software Inc., San Diego, CA, USA). The Mantel-Cox log-rank and the Gehan-Breslow-Wilcoxon tests were both applied to compare time to event variables. Whereas the Gehan-Breslow-Wilcoxon analysis gives more weight to early events, the Mantel-Cox log-rank method emphasizes late occurring events. Since progression and death in relapsing GCT patients tend to be early events, we decided to apply Gehan-Breslow-Wilcoxon P values. However, since the Mantel-Cox log-rank method is more commonly used, both P values are reported. The χ 2 test was used for contingency tables. Categorical data were summarized using absolute frequencies and percentages. A difference of P < 0.05 was considered significant.
Results
Outcome after the first autologous transplant
The 5-year PFS and the 5-year OS of the entire cohort (n = 96) were 46.2 and 48.5%, respectively (Fig. 1a, b) , and the median PFS was 22.8 months and the median OS was 51.6 months. At the last follow-up, 50 of 96 patients (52.1%) were still alive, and 47 of 96 patients (49.0%) were without evidence of disease. The d100 treatment-related mortality was 6.3% (6 of 96 patients). Three patients did not receive a planned further HDCT cycle due to toxicity; reasons were cardiac toxicity in one patient, combined renal and ototoxicity in one patient, and ototoxicity in one patient.
Based on the remission status after the first HDCT cycle, patients were divided into a group of patients who achieved CR after the first HDCT (n = 19) and patients without early CR2 after the first HDCT (n = 77). The 5-year PFS were 62.0 vs. 42.8% (log-rank P = 0.0698; Gehan-Breslow-Wilcoxon P = 0.0301) with a median PFS of 9.6 months in the non-early CR2 group, whereas the median PFS was not achieved in the early CR2 group (Fig. 1c) . The 5-year OS rates were 56.9 vs. 46.2% (logrank P = 0.1517; Gehan-Breslow-Wilcoxon P = 0.0684, respectively), and the median OS was 34.8 months for the non-early CR2 group, whereas it was not reached in the early CR2 group (Fig. 1d) .
Factors predicting CR2 after the first ASCT (early CR2)
Overall, 37 of 95 (38.9%) patients achieved a CR after firstline chemotherapy (CR1). Thirteen of these 37 (35.1%) patients reached a second CR after the first HDCT cycle (CR2). In contrast, only 6 of 57 (10.5%) patients who never achieved CR1 reached an early CR2 after the first HDCT with ASCT (P = 0.0037). In addition, one-third of the HDCT high-dose chemotherapy, CR2 patients considered to be in second complete remission after HDCT, NSGCT nonseminoma germ cell tumor, β-HCG human chorionic gonadotropin, CNS central nervous system
patients not in CR1 after BEP chemotherapy underwent surgical resection of residual tumor after first-line chemotherapy (31 of 95, 32.6%). The probability to achieve early CR2 was not different in patients relapsing with or without first-line resection of residual tumor lesions ( Table 1) . The duration between initial diagnosis of GCT and first HDCT tended to be longer in patients with early CR2 after the first HDCT cycle. Seven of 19 (36.8%) patients with early CR2 had a late relapse, defined by HDCT more than 2 years after first diagnosis, whereas only 12 of 77 patients (15.6%) with a late relapse were observed in the group without early CR2 (P = 0.0373) ( Table 2) .
We found that histology predicted response to a first HDCT in relapsing GCT patients. Thirty-four of 96 (35.4%) patients had seminomatous and 58 of 96 (60.4%) patients had nonseminomatous GCT histology. Histology remained unknown or not classifiable in 4 of 96 (4.2%) patients. Ten of 34 (29.4%) seminoma patients were in CR2 after the first HDCT cycle. In contrast, only 8 of 58 patients (13.8%) with nonseminomatous GCT were in CR2 after the first HDCT. More patients with seminomatous GCT achieved early CR2 (10 of 19 patients; 52.6%) as compared to the group without early CR2 (24 of 77 patients; 31.2%). In contrast, patients with a histology of a nonseminomatous tumor had less frequently early CR2 (8 of 19 patients; 44.4%) than patients without early CR2 (50 of 77 patients; 64.9%). Differences were even larger for mixed nonseminomatous histology, with only 21.1% (4 of 19) in the group with early CR2 compared to 46.8% (36 of 77) in patients without early CR2 (P = 0.0418).
Serum tumor markers before administration of the first HDCT were not different between the two groups (P = 0.7036 and P = 0.3893). Cut-off levels were 1,000 U/L for serum HCG and 1,000 µg/L for serum α-fetoprotein, respectively. In the group without early CR2, more patients tended to have central nervous system involvement (14.3 vs. 5.3%) or widespread involvement (59.7 vs. 47.7%), whereas fewer patients had disease exclusively localized to the retroperitoneal site (26.0 vs. 47.7%); however, these differences were not significant ( Table 2) .
Finally, the median time from the day of ASCT1 (day of stem cell retransfusion) until the day of ASCT2 was 29 days ( = ΔASCT1/2), and the median time from the day of ASCT2 (day of stem cell retransfusion) until the day of ASCT3 ( = ΔASCT2/3) was 36 days. Median ΔASCT1/2 and ΔASCT2/3 were not different between the groups with early CR2 compared to patients without early CR2.
Discussion
In remarkable contrast to first-line treatment strategies, the preferred management of relapsed GCT patients remains controversial. Up to three cycles of HDCT with ASCT represents a widely applied salvage option for such patients. We previously reported a cohort of relapsing GCT patients planned to receive three cycles of CE-HDCT/ASCT, and we found that patients achieving a CR (early CR2) after the first HDCT benefitted the most from the entire program of three HDCT cycles [18] . However, the factors predicting exquisite response to a first HDCT remained unclear. In this report, we identified response to first-line treatment, late relapse, and histology to be associated with superior response status to a first high-dose chemotherapy cycle and with better survival rates.
A widely applied prognostic score for relapsed GCT patients previously identified five prognostic factors involving primary site of tumor, response to first-line chemotherapy, progression-free interval, tumor markers at relapse, and LBB metastases [17] . In this report, we specifically investigated parameters associated with excellent response to a first HDCT, and we observed that CR after initial first-line BEP chemotherapy was strongly associated with CR after a first HDCT cycle (68.4 vs. 31.6%; P = 0.0037). In addition, an interval longer than 2 years between initial diagnosis and first HDCT was associated with higher probability to achieve a CR after a first HDCT cycle (36.8 vs. 15.6%; P = 0.0373). Furthermore, histology of mixed nonseminomatous histology was associated with inferior response after a first HDCT cycle (21.1 vs. 46.8%, P = 0.0418).
Our findings are consistent with previous reports investigating PFS at 2 years depending on response to first-line chemotherapy in a retrospective univariate Cox regression analysis (940 patients) [17] . Hazard ratios (HRs) were 2.2 (95% confidence interval (CI) 1.65-2.94) for progressive disease, and 1.4 (95% CI: 1.16-1.71) for stable disease after first-line BEP chemotherapy compared to CR (HR 1.0). Response rate to first-line chemotherapy was identified as a key factor predicting outcome, together with primary mediastinal tumor site (HR 2.7; 95% CI: 1.91-3.78). Not unexpectedly, a histology of seminoma was associated with a higher probability to achieve a CR after the first HDCT cycle. In our cohort, seminoma patients had less frequently LBB metastases, and they tended to respond better to firstline chemotherapy and relapsed less frequently.
The obvious limitations of our analysis include its retrospective design, an inevitable selection bias inherent with consecutive cohorts over a long period, and missing data. The modest sample size of our cohort limited the power to achieve significant differences in OS between patients with early CR2 vs. patients not achieving early CR2 (5-year OS 56.9 vs. 46.2%; Gehan-Breslow-Wilcoxon P = 0.0684), whereas significant differences were seen for PFS rates (5-year PFS 62.0 vs. 42.8%; Gehan-Breslow-Wilcoxon P = 0.0301).
Our data suggest that patients with mixed nonseminomatous histology and progressive disease after first-line chemotherapy showed a particularly poor response to a first CE-based HDCT cycle. For this group of poor-risk GCT patients, the role of immunotherapy is currently being evaluated as an alternative approach. An analysis of 479 formalin-fixed specimen identified programmed death receptor ligand-1 in 78 of 121 (64%) of nonseminoma specimens and 151 of 208 (73%) seminoma specimens [20] . Consequently, the benefit of the anti-PD1 antibody pembrolizumab in patients with platinum refractory GCTs is currently investigated in a multi-institutional single-arm phase II trial (NCT02499952). In conclusion, the optimum management of relapsed GCT patients remains unclear and the decision between salvage HDCT or conventional-dose chemotherapy is unanswered. The currently initiated prospective EORTC study (NCT02375204) may provide further guidance in the treatment dilemma between the available salvage strategies.
